Drug Profile
GSK 2302025A
Alternative Names: GSK2302025A; PRAME Antigen Specific Cancer Immunotherapeutic - Melanoma; PRAME-ASCI-melanomaLatest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 08 Feb 2013 GlaxoSmithKline completes enrolment in its phase I/II trial for Mestatatic melanoma (first-line therapy) in Czech Republic, France, Germany, Italy, Poland and Russia (NCT01149343)
- 03 Dec 2010 Phase-I/II clinical trials in Malignant melanoma (first-line therapy, metastatic disease) in Russia (IM)
- 24 Nov 2010 Phase-I/II clinical trials in Malignant melanoma (first-line therapy, metastatic disease) in Poland (IM)